James Waldron

GSK has unveiled an ambitious three-year plan to divert resources to its late-stage R&D programs and shift its research headquarters—but CEO Luke Miels is being tight-lipped about the extent of any job losses.

AbCellera's T-cell engager (TCE) platform has reeled in a second client this summer, with Vertex Pharmaceuticals paying $28 million upfront for a collaboration that will include autoimmune conditions.

Processa Pharmaceuticals has made a push into the autoimmune space via the acquisition of Vidya Therapeutics and its potential rival to Novartis' Rhapsido.

When Belén Garijo, M.D., Ph.D., left the top job at Germany's Merck KGaA to head over to Sanofi, she was inheriting a company in need of course correction.

Takeda has dropped another celiac disease therapy from its phase 2 pipeline, leaving the company with just one shot at treating the condition.

Apnimed has raised $192 million for its upsized IPO, with the proceeds earmarked to fund the launch of its sleep apnea pill.

One of the most closely-watched vacancies in biopharma has now been filled , with Sobi CEO Guido Oelkers, Ph.D., moving across to take up the top job at mRNA pioneer BioNTech.

BlossomHill Therapeutics plans to raise $111.7 million to fund the clinical journey of its potential challenger to Tagrisso.

Pathos AI has agreed to pay $125 million for a bispecific antibody-drug conjugate (ADC) from Alphamab Oncology, while adding another Big Pharma partner in the form of AstraZeneca.

Latigo Biotherapeutics has fleshed out its plans for an IPO to finance the development of its clinical-stage pipeline of non-opioid pain management drugs.